KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Liabilities (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Total Liabilities for 18 consecutive years, with $9.4 billion as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities rose 15.78% year-over-year to $9.4 billion; the TTM value through Mar 2026 reached $9.4 billion, up 15.78%, while the annual FY2025 figure was $9.3 billion, 10.66% up from the prior year.
  • Total Liabilities hit $9.4 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $9.3 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $9.4 billion in Q1 2026 and bottomed at $6.2 billion in Q3 2022.
  • Average Total Liabilities over 5 years is $7.6 billion, with a median of $7.4 billion recorded in 2024.
  • Year-over-year, Total Liabilities dropped 2.72% in 2022 and then rose 18.7% in 2024.
  • Regeneron Pharmaceuticals' Total Liabilities stood at $6.6 billion in 2022, then increased by 8.5% to $7.1 billion in 2023, then increased by 18.27% to $8.4 billion in 2024, then rose by 10.66% to $9.3 billion in 2025, then increased by 1.54% to $9.4 billion in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $9.4 billion, $9.3 billion, and $9.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.